MX2016002560A - Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir. - Google Patents

Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir.

Info

Publication number
MX2016002560A
MX2016002560A MX2016002560A MX2016002560A MX2016002560A MX 2016002560 A MX2016002560 A MX 2016002560A MX 2016002560 A MX2016002560 A MX 2016002560A MX 2016002560 A MX2016002560 A MX 2016002560A MX 2016002560 A MX2016002560 A MX 2016002560A
Authority
MX
Mexico
Prior art keywords
darunavir
ritonavir
emtricitabine
tenofovir
dosage form
Prior art date
Application number
MX2016002560A
Other languages
Spanish (es)
Inventor
Hrakovsky Julia
Shahar Nitzan
Haronsky Elina
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2016002560A publication Critical patent/MX2016002560A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to an oral unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir and a monolithic tablet comprising Darunavir and Ritonavir and their use to treat HIV infection.
MX2016002560A 2013-08-29 2014-08-28 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir. MX2016002560A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361871674P 2013-08-29 2013-08-29
PCT/IB2014/001637 WO2015028875A2 (en) 2013-08-29 2014-08-28 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir

Publications (1)

Publication Number Publication Date
MX2016002560A true MX2016002560A (en) 2016-10-26

Family

ID=51830545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002560A MX2016002560A (en) 2013-08-29 2014-08-28 Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir.

Country Status (8)

Country Link
EP (1) EP3038607A2 (en)
AR (1) AR097512A1 (en)
CA (1) CA2918707A1 (en)
HK (1) HK1220390A1 (en)
IL (1) IL244107A0 (en)
MX (1) MX2016002560A (en)
TW (1) TW201542212A (en)
WO (1) WO2015028875A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015245217A1 (en) * 2014-04-08 2016-10-13 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
KR101777564B1 (en) 2016-05-30 2017-09-12 영남대학교 산학협력단 Tablet composition comprising tenofovir disoproxil free base and preparation method thereof
WO2018153977A1 (en) * 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
CN108727401A (en) * 2017-04-20 2018-11-02 盐城迪赛诺制药有限公司 Darunavir novel crystal forms and its preparation method and application

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
KR100336699B1 (en) 1992-08-25 2002-05-13 윌리암스 로저 에이 Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
MY145265A (en) 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
AU2004206827A1 (en) 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
DE602005009366D1 (en) * 2004-07-08 2008-10-09 Tibotec Pharm Ltd COMBINATION OF TENOFOVIR, RITONAVIR AND TMC114
AR045841A1 (en) * 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie A SOLID PHARMACEUTICAL COMPOSITION THAT INCLUDES THE TIAZOLIL METHYL ESTER OF THE ACID [5S- (5R *, 8R *, 10R *, 11R *)] -10- HYDROXY-2-METHYL-5- (1-METHYTILE) -1- [2 - (1-METHYLE) -4-TIAZOLIL] -3,6-DIOXO-8,11-BIS (PHENYLMETIL) -2,4,7,12- TETRAAZATRIDECAN-13-OICO AND A PROCEDURE TO PREPARE IT.
TWI471145B (en) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
PL2178513T3 (en) * 2007-06-22 2011-09-30 Bristol Myers Squibb Holdings Ireland Tableted compositions containing atazanavir
PA8809601A1 (en) 2007-12-24 2009-07-23 Cipla Ltd ANTI-RETROVIRAL COMBINATION
CA2744211A1 (en) * 2008-11-21 2010-05-27 Ultimorphix Technologies B.V. Wet granulation of tenofovir, emtricitabine and efavirenz
WO2011013110A1 (en) * 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
EP2332532A1 (en) * 2009-11-20 2011-06-15 Assistance Publique, Hopitaux De Paris New multi-therapy administration patterns suitable for treating persons affected by human immunodeficiency virus (HIV)
EP2332544A1 (en) 2009-11-20 2011-06-15 Assistance Publique, Hopitaux De Paris New pharmaceutical composition suitable for treating persons affected by human immunodeficiency virus (HIV)
ES2598823T3 (en) 2011-07-07 2017-01-30 Janssen R&D Ireland Darunavir formulations
WO2013057469A1 (en) 2011-10-20 2013-04-25 Cipla Limited Pharmaceutical antiretroviral compositions
GB201118182D0 (en) * 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
GB201119032D0 (en) * 2011-11-03 2011-12-14 Isis Innovation Multisomes: encapsulated droplet networks
EA026138B1 (en) * 2012-02-03 2017-03-31 Джилид Сайэнс, Инк. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
US20150045400A1 (en) * 2012-03-01 2015-02-12 Bandi Parthasaradhi Reddy Ritonavir compositions
IN2013MU01749A (en) * 2013-05-15 2015-06-26 Cipla Ltd

Also Published As

Publication number Publication date
AR097512A1 (en) 2016-03-23
WO2015028875A8 (en) 2016-09-01
WO2015028875A2 (en) 2015-03-05
WO2015028875A3 (en) 2015-11-19
HK1220390A1 (en) 2017-05-05
IL244107A0 (en) 2016-04-21
CA2918707A1 (en) 2015-03-05
TW201542212A (en) 2015-11-16
EP3038607A2 (en) 2016-07-06

Similar Documents

Publication Publication Date Title
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
MY187540A (en) Compounds active towards bromodomains
EA201792591A1 (en) PHARMACEUTICAL PREPARATIONS
IL248095A0 (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
IL243786A0 (en) Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir
PH12016501841A1 (en) Immunosuppressant formulation
MX2016002560A (en) Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir.
MX2017003928A (en) Long acting pharmaceutical compositions.
MX2017012596A (en) A pharmaceutical composition and the use thereof.
MX2018005358A (en) Optimised high-dose mesalazine-containing tablet.
MX2016006087A (en) Rapidly disintegrating formulations and methods of use.
CY1119522T1 (en) (R) - PILINDOL AND THE PHARMACEUTICALALLY ACCEPTABLE SALTS FOR USE IN MEDICINE
MX2016004078A (en) Hiv treatment formulation of atazanavir and cobicistat.
MA40496A (en) Capsaicinoids and uses thereof as medicaments
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
EP4282485A3 (en) Dosage regimen for pegylated interferon
PH12017501979A1 (en) Pharmaceutical compound
IN2013CH05288A (en)
IN2013MU03370A (en)
IN2014DN07895A (en)
IN2013MU02015A (en)
EP2968127A4 (en) Low-glycerin formulations for hiv treatment and prevention
MD4291C1 (en) Medicinal preparation for the treatment of otitis
PH12017501982A1 (en) Pharmaceutical compound
CR20170601A (en) PHARMACEUTICAL FORMULATIONS THAT INCLUDE TENOFOVIR AND EMTRICITABINA